TGTX — TG THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1001316 ·
Last close
$57.12
Market Cap
$8.74B
52W High
$59.30
52W Low
$33.23
ADV30
2,715,277
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 204,918,000 | 171,408,000 | 34,795,000 | 19,777,000 | 1,528,837,000 | 442,209,000 | 945,706,000 |
| Dec 2025 | 192,574,000 | 154,432,000 | 50,494,000 | 23,037,000 | 1,063,253,000 | 79,148,000 | 415,233,000 |
| Sep 2025 | 161,709,000 | 133,616,000 | 29,365,000 | 390,895,000 | 1,025,024,000 | 74,081,000 | 417,806,000 |
| Jun 2025 | 141,148,000 | 122,210,000 | 34,843,000 | 28,187,000 | 702,613,000 | 129,126,000 | 426,181,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,772,000
Investing CF
$13,799,000
Financing CF
$-89,729,000
CapEx
$-214,000
Dividends Paid
—
Buybacks
$-91,240,000
EPS Diluted TTM
$2.77
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,082,015,000
Inventory
$125,586,000
Receivables
$305,628,000
ST Investments
$62,822,000
EBIT TTM
$134,117,000
Pretax Income TTM
$107,390,000
Interest Exp TTM
$26,727,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$700,348,992
EBITDA
$149,580,000
Free Cash Flow
$-30,164,876
Enterprise Value
$8,609,288,192
Total Cash
$514,430,016
Total Debt
$753,556,992
Shares Out
153,083,580
Trailing EPS
$2.86
Book Value
$4.11
ROE
112.6%
ROA
8.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 616,287,000 | 123,324,000 | 447,179,000 | 1,063,253,000 | 415,233,000 | — | -24,772,000 |
| Dec 2024 | 329,004,000 | 41,929,000 | 23,383,000 | 577,690,000 | 355,326,000 | — | -40,517,000 |
| Dec 2023 | 233,662,000 | 20,633,000 | 12,672,000 | 329,587,000 | 169,085,000 | — | -31,413,000 |
| Dec 2022 | 2,785,000 | -218,316,000 | -223,812,000 | 193,572,000 | 134,985,000 | — | -176,170,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.01
Max Pain — expiry 2026-07-17
max pain strike: $48.00 · spot: $57.12 · call oi: 12,188 · put oi: 5,515
Expected Move to 2026-07-17:
±$4.03
(7.05%) —
implied range
$53.09 –
$61.14
· ATM straddle on $55.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALKS | Alkermes plc. | $8.66B | $51.94 | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.85B | $83.58 | — |
| SYRE | Spyre Therapeutics, Inc. | $8.49B | $97.74 | — |
| PTGX | Protagonist Therapeutics, Inc | $8.45B | $131.42 | — |
| PRAX | Praxis Precision Medicines, Inc. | $9.06B | $324.99 | — |
News headlines (Yahoo Finance, 1h cache)
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial
2026-07-09 10:40 · Yahoo
TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News
2026-07-09 04:36 · Yahoo
2 Fast-Growing Pharmaceutical Stocks to Buy Now
2026-07-09 00:25 · Yahoo
Can TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI’s Role Beyond Multiple Sclerosis?
2026-07-08 21:15 · Yahoo
Is TG Therapeutics (TGTX) Fully Valued Following Its Schizophrenia Trial Update?
2026-07-08 16:17 · Yahoo
TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch
2026-07-07 20:13 · Yahoo
Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says
2026-07-07 15:04 · Yahoo
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
2026-07-07 12:58 · Yahoo
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
2026-07-06 11:30 · Yahoo
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
2026-07-03 12:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.